Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards

Pharmacological Research

Volumn 59, Issue 1, 2009, Pages 62-68

  Peiro A M ^a,b   Novalbos, J ^c,d   Zapater, P ^a,b,d   Moreu, R ^b   Lopez Rodriguez R ^c,d   Rodriguez V ^c,d   Abad Santos, F ^c,d   Horga, J F ^a,b,d  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

Bioequivalence study; CYP2C9*3; Pharmacogenetic; Spaniards; Tenoxicam

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA; TENALGIN; TENOXICAM; UNCLASSIFIED DRUG;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ETHNIC GROUP; FEMALE; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

EID: 58149476593     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.09.018     Document Type: Article

References (37)

1. Todd P.A., and Clissold S.P. Tenoxicam: an update of its pharmacology and therapeutic efficacy in rheumatic diseases. Drugs 41 (1991) 625-646
2. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (1996) 341-349
3. Lee C.R., Goldstein J.A., and Pieper J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12 (2002) 251-263
4. Human Cytochrome P450 (CYP) Nomenclature Committee Website. http://www.imm.ki.se/CYPalleles.htm (accessed 05/19/2008).
5. Garcia-Martin E., Martinez C., Ladero J.M., and Agundez J.A. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10 (2006) 29-40
6. Gardiner S.J., and Begg E.J. Pharmacogenetics, drug-metabolizing enzymes and clinical practice. Pharmacol Rev 58 (2006) 522-590
7. Bahadur N., Leathart J.B., Mutch E., Steimel-Crespi D., Dunn S.A., Gilissen R., et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6-alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64 (2002) 1579-1589
8. Cavaco I., Piedade R., Gil J.P., and Ribeiro V. CYP2C8 polymorphism among the Portuguese. Clin Chem Lab Med 44 (2006) 168-170
9. Dorado P., Berecz R., Norberto M.J., Yasar U., Dahl M.L., and LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 59 (2003) 221-225
10. ®. Laboratorio Atral, S.A. (Portugal); 2004.
11. CPMP. Note for guidance on investigation for Bioability and Bioequivalence. (CPMP/EWP/QWP/1401/98). http://www.emea.europa.eu (accessed: 03/15/2008); January 2002.
12. Hauschke D., Steinijans V.W., and Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28 (1990) 72-78
13. Shelepova T., Nafziger A.N., Victory J., Kashuba A.D., Rowland E., Zhang Y., et al. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 45 (2005) 1413-1421
14. Francis R.J., Allen J.G., Looi D., Dixon J.S., Bird H.A., and Wright V. Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. Eur J Metab Pharmacokinet 12 (1987) 59-63
15. Xie H.G., Prasad H.C., Kim R.B., and Stein C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54 (2002) 1257-1270
16. Schwarz U.I. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33 Suppl 2 (2003) 23-30
17. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77 (2005) 1-16
18. Rettie A.E., and Jones J.P. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45 (2005) 477-494
19. Kirchheiner J., and Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 1770 (2007) 489-494
20. Miners J.O., Birkett D.J., and Cytochrome. P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45 (1998) 525-538
21. Perini J.A., Vianna-Jorge R., Brogliato A.R., and Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 78 (2005) 362-369
22. Lee C.R., Pieper J.A., Frye R.F., Hinderliter A.L., Blaisdell J.A., and Goldstein J.A. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and*1/*3 genotypes. Eur J Clin Pharmacol 58 (2003) 791-794
23. García-Martín E., Martínez C., Tabarés B., Frías J., and Agúndez J.A. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 76 (2004) 119-127
24. Vianna-Jorge R., Perini J.A., Rorsinelli E., and Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 76 (2004) 18-26
25. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267 (1992) 83-90
26. Yasar U., Lundgren S., Eliasson E., Bennet A., Wiman B., de Faire U., et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299 (2002) 25-28
27. Daly A.K., and King B.P. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13 (2003) 247-252
28. Aynacioglu A.S., Brockmöller J., Bauer S., Sachse C., Güzelbey P., Ongen Z., et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48 (1999) 409-415
29. Kirchheiner J., Meineke I., Freytag G., Meisel C., Roots I., and Brockmöller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 72 (2002) 62-75
30. Thijssen H.H., and Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther 74 (2003) 61-68
31. Rodrigues A.D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug Metab Dispos 33 (2005) 1567-1575
32. Brockmöller J., and Roots I. Assessment of liver metabolic function. Clin Pharmacokinet 27 (1994) 216-248
33. Aithal G., Day C., Kesteven P., and Daly A. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
34. Chan A.T., Tranah G.J., Giovannucci E.L., Hunter D.J., and Fuchs C.S. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2 (2004) 704-712
35. Tranah G.J., Chan A.T., Giovannucci E., Ma J., Fuchs C., and Hunter D.J. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. Mol Carcinog 44 (2005) 21-30
36. Martínez C., Blanco G., Ladero J.M., García-Martín E., Taxonera C., Gamito F.G., et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 141 (2004) 205-208
37. Kohl C., and Steinkellner M. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 28 (2000) 161-168